View More Recent Stories

Mar 24, 2022 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Mar 9, 2022 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Mar 8, 2022 04:30PM Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences
Feb 24, 2022 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Feb 23, 2022 04:05PM Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Feb 15, 2022 04:10PM Arcus Biosciences to Participate in the Upcoming Investor Conferences
Feb 9, 2022 05:04PM Arcus Biosciences Announces New Employment Inducement Grants
Jan 25, 2022 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Jan 11, 2022 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Jan 10, 2022 08:07AM Arcus Biosciences (RCUS) Provides Update on Clinical Programs, Including Key 2022 Milestones
Jan 10, 2022 08:00AM Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
Dec 24, 2021 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Dec 21, 2021 04:35PM Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-stage Programs and New Research Collaboration
Dec 21, 2021 04:35PM Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
Dec 9, 2021 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Nov 30, 2021 05:50AM Arcus Biosciences (RCUS) Announces Taiho Exercised Option for an Exclusive License to Anti-TIGIT Program in Japan and Certain Territories in Asia
Nov 30, 2021 01:00AM Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
Nov 24, 2021 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Nov 22, 2021 04:10PM Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
Nov 18, 2021 07:03AM Gilead (GILD) Exercises Options to Three Arcus Biosciences (RCUS) Clinical-stage Programs and Adds Research Collaboration
Nov 18, 2021 07:00AM Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration
Nov 18, 2021 07:00AM Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
Nov 9, 2021 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Nov 8, 2021 04:10PM Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab
Nov 2, 2021 04:10PM Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights
Aug 5, 2021 04:10PM Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights
Jun 24, 2021 04:10PM Arcus Biosciences Announces New Employment Inducement Grants
Jun 23, 2021 04:11PM Arcus Biosciences (RCUS) Announces Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High NSCLC at First Interim Analysis
Jun 23, 2021 04:10PM Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Random
May 19, 2021 05:09PM Arcus Biosciences (RCUS) Presents Early Data from ARC-6, a Phase 1b/2 Study Evaluating Etrumadenant-Based Combinations in Metastatic Castrate-Resistant Prostate Cancer at the 2021 ASCO Annual Meeting
May 19, 2021 05:05PM Arcus Biosciences Presents Early Data from ARC-6, a Phase 1b/2 Study Evaluating Etrumadenant-Based Combinations in Metastatic Castrate-Resistant Prostate Cancer at the 2021 ASCO Annual Meeting
View More Recent Stories